Unicycive Therapeutics Inc Ordinary Shares UNCY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline
-
What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline
-
UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
-
Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit
-
What Should Unicycive Therapeutics, Inc. Investors Know After 39.1% Stock Drop? The Law Offices of Frank R. Cruz Outlines Securities Fraud Class Action Lead Plaintiff Deadline
-
Unicycive Therapeutics Shares Rise After FDA Accepts Resubmitted NDA
-
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
-
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Trading Information
- Previous Close Price
- $3.94
- Day Range
- $3.71–4.02
- 52-Week Range
- $3.35–8.74
- Bid/Ask
- $3.85 / $3.89
- Shares Outstanding
- 27.86M
- Market Cap
- $108.36M
- Volume/Avg
- 1M / 862,359
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.unicycive.com
Valuation
|
Metric
|
UNCY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.03 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
UNCY
|
|---|---|
Quick Ratio | 3.28 |
Current Ratio | 3.81 |
Interest Coverage | −872.57 |
Quick Ratio
UNCY
Profitability
|
Metric
|
UNCY
|
|---|---|
Return on Assets (Normalized) | −49.93% |
Return on Equity (Normalized) | −75.91% |
Return on Invested Capital (Normalized) | −78.70% |
Return on Assets
UNCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|gBd@ng& | LOCK|@?qL | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@$kz@> | LOCK|df<$ | $83B | |||
| Moderna Inc
MRNA
| LOCK|qDyHrNy | LOCK|dh | $80B | |||
| argenx SE ADR
ARGX
| LOCK|Fz$RR^ | LOCK|Y> | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&!Yy#%l | LOCK|@<< | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|gd$>GQ | LOCK|n#wC | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!%jJj>!k | LOCK|$cfYt | $28B | |||
| Incyte Corp
INCY
| LOCK|j^!V<> | LOCK|wh@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|x%?wXRp | LOCK|%s# | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%?&FR&q | LOCK|>BV | $14B |
United States